The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Leach, M O, Brindle, K M, Evelhoch, J L, Griffiths, J R, Horsman, M R, Jackson, A, Jayson, G C, Judson, I R, Knopp, M V, Maxwell, R J, McIntyre, D, Padhani, A R, Price, P, Rathbone, R, Rustin, G J, Tofts, P S, Tozer, G M, Vennart, W, Waterton, J C, Williams, S R, Workman, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Workshop Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362033/
https://www.ncbi.nlm.nih.gov/pubmed/15870830
http://dx.doi.org/10.1038/sj.bjc.6602550
_version_ 1782153362552127488
author Leach, M O
Brindle, K M
Evelhoch, J L
Griffiths, J R
Horsman, M R
Jackson, A
Jayson, G C
Judson, I R
Knopp, M V
Maxwell, R J
McIntyre, D
Padhani, A R
Price, P
Rathbone, R
Rustin, G J
Tofts, P S
Tozer, G M
Vennart, W
Waterton, J C
Williams, S R
Workman, P
author_facet Leach, M O
Brindle, K M
Evelhoch, J L
Griffiths, J R
Horsman, M R
Jackson, A
Jayson, G C
Judson, I R
Knopp, M V
Maxwell, R J
McIntyre, D
Padhani, A R
Price, P
Rathbone, R
Rustin, G J
Tofts, P S
Tozer, G M
Vennart, W
Waterton, J C
Williams, S R
Workman, P
author_sort Leach, M O
collection PubMed
description Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.
format Text
id pubmed-2362033
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23620332009-09-10 The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Leach, M O Brindle, K M Evelhoch, J L Griffiths, J R Horsman, M R Jackson, A Jayson, G C Judson, I R Knopp, M V Maxwell, R J McIntyre, D Padhani, A R Price, P Rathbone, R Rustin, G J Tofts, P S Tozer, G M Vennart, W Waterton, J C Williams, S R Workman, P Br J Cancer Workshop Report Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used. Nature Publishing Group 2005-05-09 2005-05-03 /pmc/articles/PMC2362033/ /pubmed/15870830 http://dx.doi.org/10.1038/sj.bjc.6602550 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Workshop Report
Leach, M O
Brindle, K M
Evelhoch, J L
Griffiths, J R
Horsman, M R
Jackson, A
Jayson, G C
Judson, I R
Knopp, M V
Maxwell, R J
McIntyre, D
Padhani, A R
Price, P
Rathbone, R
Rustin, G J
Tofts, P S
Tozer, G M
Vennart, W
Waterton, J C
Williams, S R
Workman, P
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
title The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
title_full The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
title_fullStr The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
title_full_unstemmed The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
title_short The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
title_sort assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
topic Workshop Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362033/
https://www.ncbi.nlm.nih.gov/pubmed/15870830
http://dx.doi.org/10.1038/sj.bjc.6602550
work_keys_str_mv AT leachmo theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT brindlekm theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT evelhochjl theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT griffithsjr theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT horsmanmr theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT jacksona theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT jaysongc theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT judsonir theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT knoppmv theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT maxwellrj theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT mcintyred theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT padhaniar theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT pricep theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT rathboner theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT rustingj theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT toftsps theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT tozergm theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT vennartw theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT watertonjc theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT williamssr theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT workmanp theassessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT leachmo assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT brindlekm assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT evelhochjl assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT griffithsjr assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT horsmanmr assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT jacksona assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT jaysongc assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT judsonir assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT knoppmv assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT maxwellrj assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT mcintyred assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT padhaniar assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT pricep assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT rathboner assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT rustingj assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT toftsps assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT tozergm assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT vennartw assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT watertonjc assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT williamssr assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations
AT workmanp assessmentofantiangiogenicandantivasculartherapiesinearlystageclinicaltrialsusingmagneticresonanceimagingissuesandrecommendations

Ejemplares similares